

## GLOSSARY OF REGULATORY HEALTHCARE ACRONYMS & ABBREVIATIONS

[www.topra.org/glossary](http://www.topra.org/glossary)

*Note: Medical prescription abbreviations can be found at [www.abbreviations.com/acronyms/PRESCRIPTION](http://www.abbreviations.com/acronyms/PRESCRIPTION)*

**1-1-1** – One dossier, one European scientific assessment, one decision for marketing authorisation  
**3Rs** – Replacement, refinement and reduction (in research using animals)  
**510(k)** – Medical device premarket notification (US FDA)  
**AA** – Accelerated assessment/approval  
**AAC** – Accelerated Access Collaborative (UK)  
**AADA** – Abbreviated antibiotic drug application  
**AAP** – Accelerated approval pathway (US) – **but also:**  
**AAP** – Accelerated assessment procedure (EU)  
**AAPS** – American Association of Pharmaceutical Scientists  
**AAR** – Accelerated access review  
**AAS** – Atomic absorption spectroscopy  
**AAV** – Adeno-associated virus  
**ABHI** – Association of British Healthcare Industries (medical devices sector)  
**ABPI** – Association of the British Pharmaceutical Industry  
**A-CASI** – Audio computer-assisted self-interviewing  
**ACO** – Addendum to clinical overview  
**ACRP** – Association of Clinical Research Professionals  
**ACSS** – Australia, Canada, Singapore, Switzerland Consortium  
**ACT** – Artemisinin-based combination therapy  
**ACTD** – ASEAN common technical dossier (see **ASEAN**)  
**ACVM** – Agricultural Compounds and Veterinary Medicines (New Zealand)  
**ADaM** – Analysis data model  
**ADC** – Additional data collection – **but also:**  
**ADC** – Antibody–drug conjugate  
**ADCC** – Antibody-dependent cellular cytotoxicity  
**ADE** – Adverse device event (AE judged to be related to the medical device)  
**ADEC** – Australian Drug Evaluation Committee  
**ADI** – Acceptable daily intake  
**ADME** – Absorption, distribution, metabolism and excretion/elimination (also **AME** – absorption, metabolism, excretion/elimination)  
**ADR** – Adverse drug reaction  
**ADROIT** – Adverse Drug Reactions On-Line Tracking System  
**ADVAC** – Ad hoc group on veterinary vaccine availability (CVMP)  
**ADVENT** – Ad Hoc Expert Group on Veterinary Novel Therapies  
**AE** – Adverse event  
**AEFI** – Adverse event following immunisation  
**AEGIS** – Adverse Experience Gathering Information System  
**AEM** – Agencia Espanola Medicamento (Spain)  
**AEMPS** – Agencia Española de Medicamentos y Productos Sanitarios (Spain)  
**AEPAR** – Asociación Española de Profesionales de Actividades de Registro (Spanish Regulatory Affairs Association)  
**AERS** – Adverse event reporting system (US FDA)  
**AESGP** – Association Européenne des Spécialités Pharmaceutiques Grand Public (Association of the European Self-Medication Industry)  
**AF** – Application Form  
**AFAR** – Association Française des Affaires Réglementaires (French Regulatory Affairs Association)  
**AFDO** – Association of Food and Drug Officials (US)  
**AFMPS** – Agence Fédérale des Médicaments et des Produits de Santé (Belgium)  
**Afssaps** – former French regulatory agency (Agence Française de Sécurité Sanitaire des Produits de Santé) – replaced by **ANSM** in 2012 (see below)  
**AGES PharmMED** – Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH (Austria's medicines & devices agency)  
**AHSC** – Academic Health Science Centre (UK)  
**AHWP** – Asian Harmonisation Working Party  
**AI** – Adverse incident (medical devices sector) – **and also:**  
**AI** – Artificial intelligence

**AIFA** – Agenzia Italiana del Farmaco (Italy's health authority)  
**AIM** – Active ingredient manufacturer  
**AIMD** – Active implantable medical device  
**AITTS** – Adverse Incident Tracking System (medical devices sector)  
**AKP** – Alkaline phosphatase  
**ALARP** – As low as reasonably practical  
**ALATF** – As low as technically feasible (terminology superseded by “ALARP” – see above)  
**ALIMS** – Medicines and Medical Devices Agency (Serbia)  
**ALL** – Acute lymphocytic leukaemia  
**ALT** – Alanine aminotransferase (ALT = SGPT)  
**AM** – Agence du Medicament (France)  
**AMA** – American Medical Association  
**AMEG** – AntiMicrobial advice ad hoc Expert Group  
**AMI** – Acute myocardial infarct  
**AML** – Acute myeloid leukemia  
**AMM** – Autorisation de mise sur le marché (France) = Product licence  
**AMP** – Authorised medicinal product – **but also:**  
**AMP** – Auxiliary medicinal product (*formerly non-investigational medicinal product, NIMP*)  
**AMR** – Antimicrobial resistance  
**AMRH** – African Medicines Regulatory Harmonisation  
**ANADA** – Abbreviated New Animal Drug Application (US)  
**ANDA** – Abbreviated new drug application  
**ANDS** – Abbreviated new drug submission (Canada)  
**ANMV** – Agence nationale du médicament vétérinaire (French vet medicines agency)  
**ANOVA** – Analysis of Variance  
**ANPR** – Advanced notice of proposed rulemaking (US)  
**ANSES** – Agence Française de Sécurité Sanitaire des Aliments Agence nationale du médicament vétérinaire  
**ANSM** – French regulatory agency (Agence nationale de sécurité du médicament et des produits de santé)  
[formerly **Afssaps**]  
**ANZTPA** – Australia New Zealand Therapeutic Products Agency (scheduled to come into force in 2016 – replacing Australia's TGA and New Zealand's Medsafe)  
**AO** – Auditing organisation  
**AOAC** – Association of Official Analytical Chemists (US)  
**AOB** – Any other business  
**AP** – Accredited person – **but also:**  
**AP** – Adaptive pathway  
**APEC** – Asia-Pacific Economic Cooperation  
**APHIS** – Animal and Plant Health Inspection Service (US)  
**API** – Active pharmaceutical ingredient  
**APIC** – Active Pharmaceutical Ingredients Committee  
**APLB** – Advertising and Promotional Labeling Branch (FDA's CBER)  
**APMA** – Australian Pharmaceutical Manufacturers Association  
**APVA** – Additional pharmacovigilance activities  
**APVMA** – Australian Pesticides and Veterinary Medicines Authority (Australia)  
**AQL** – Acceptable quality level  
**AR** – Adverse reaction – **but also:**  
**AR** – Assessment Report (EU) – **and also:**  
**AR** – Authorised representative  
**ARfD** – Acute reference dose (veterinary)  
**ARMAs** – Additional risk minimisation activities  
**ARMMs** – Additional risk minimisation measures  
**AS** – Active Substance  
**ASAP** – Accelerated Stability Assessment Program  
**ASCII** – American Standard Code for Information Interchange Quality Assurance  
**ASDI** – Acceptable single-dose intake  
**ASEAN** – Association of Southeast Asian Nations  
**ASMF** – Active Substance Master File  
**ASMF WG** – Working Group on Active Substance Master File procedures  
**ASPR** – Anonymised single patient report (formerly ASPP – anonymised single patient printout)  
**ASR** – Annual safety report  
**AST** – Aspartate aminotransaminase (AST = SGOT)  
**ATA** – Alternatives to antibiotics

**ATC** – Anatomical – therapeutic – chemical (WHO) – **but also:**  
**ATC** – Animal Test Certificate (UK) – **and also:**  
**ATC Code** – Anatomical Therapeutic Chemical Code  
**ATC Vet Code** – Anatomical Therapeutic Chemical Veterinary Code  
**ATC(/DDD)** – Anatomical Therapeutic Chemical classification system (with Defined Daily Doses)  
**ATD** – Access to documents (EMA policy) – **and also:**  
**ATD** – Anticipated therapeutic dose – **and also:**  
**ATD** – Anti-tampering device  
**ATECT** – Advanced T-cell Engineering for Cancer Therapy  
**ATF** – Alcohol – Tobacco and Firearms (Bureau of) (US)  
**ATMPs** – Advanced therapy medicinal products (aka “advanced therapies”)  
**ATU** – Authorisation for temporary use  
**AUC<sub>∞</sub>** – Area under the concentration time curve between zero and infinity  
**AUC<sub>x</sub>** – Area under the curve during a given time  
**AVEG** – AIDS Vaccine Evaluation Group  
**AWP** – Antimicrobials Working Party  
**AXREM** – Association of X-ray Equipment Manufacturers  
**AYA** – Adolescents and young adults

**BBB**

**BA** – Bioavailability  
**BA/BE** – Bioavailability/bioequivalence  
**BACPAC** – Bulk active chemical post approval changes (US)  
**BAI** – Breath actuated inhaler  
**BAID** – Batch identifier  
**BAN** – British Approved Name  
**BAP** – Biotechnology Action Programme/Biosimilars Action Plan  
**BARQA** – British Association of Research Quality Assurance  
**BCS** – Biopharmaceutics Classification System  
**bd/bid** – twice a day (*Latin: bis in die*)  
**BDA** – Bulgarian drug agency  
**BE** – Bioequivalence  
**BEMA** – Benchmarking of European Medicines Agencies  
**BfArM** – Federal Institute for Drugs and Medical Devices (Bundesinstituts für Arzneimittel und Medizinprodukte) (Germany’s regulatory authority)  
**BGMA** – British Generic Manufacturers Association  
**BIBRA** – British Industrial Biological Research Association  
**BIND** – Biological investigational new drug  
**BIO** – Biotechnology Industry Organization (US)  
**BLA** – Biologics license application (US)  
**BM** – Bone marrow  
**BMA** – British Medical Association  
**BMD** – Bone mineral density  
**BMG** – Bundesministerium für Gesundheit = Federal Ministry of Health (Germany)  
**BMGF** – Bundesministerium fuer Gesundheit und Frauen (Austria)  
**BMWP** – Biosimilar Medicinal Products Working Party  
**BNF** – British National Formulary  
**BoH** – Board of Health  
**BOS** – Break-out session  
**BP** – Blood pressure – **but also:**  
**BP** – British Pharmacopoeia  
**BPC** – British Pharmacopoeia Commission – **but also:**  
**BPC** – Bulk pharmaceutical chemicals  
**BPCA** – Best Pharmaceuticals in Children Act (US)  
**BPG** – Best Practice Guide  
**BPI** – Bundesverband der Pharmazeutischen Industrie (German pharmaceutical industry trade association)  
**BPR** – Biocidal Products Regulation  
**BPWP** – Blood Products Working Party (EMA)  
**Br** – Barrier reared (in older reports – ‘Brown’)  
**BRAS** – Belgian Regulatory Affairs Society  
**BRAT** – Benefit-Risk Action Team

**BRIC** – Brazil, Russia, India & China  
**BRICK**– Brazil, Russia, India, China & (South) Korea  
**BRICS** – Brazil, Russia, India, China & South Africa  
**BROMI** – Better Regulation of Over the Counter Medicines Initiative  
**BSE** – Bovine Spongiform Encephalopathy  
**BTD** – Breakthrough therapy designation (US)  
**BTDR** – Breakthrough therapy designation request  
**BTF** – Brexit Task Force  
**BWP** – Biotech Working Party (EMA)

**CCC**  
**C&P** – Chemistry and Pharmacy  
**CA** – Commercial appraisal – **but also:**  
**CA** – Competent authority  
**CAC** – Codex Alimentarius Commission (veterinary sector)  
**CAD** – Coronary artery disease  
**CADREAC** – Collaboration agreement between drug regulatory authorities of European Union associated countries (also **nCADREAC** – new Collaboration Agreement)  
**CADTH** – Canadian Agency for Drugs and Technologies in Health (formerly CCOHTA)  
**CAMD** – Competent Authorities for Medical Devices  
**CAMS** – Chinese Academy of Medical Sciences  
**CANDA** – Computer assisted new drug application  
**CAO** – Central Agricultural Office (Hungary)  
**CAP** – Centrally authorised product  
**CAPA** – Corrective action and preventive action  
**CAPA plan** – Corrective and preventive action plan  
**CAPLA** – Computer Assisted Product Licence Application  
**CAPRA** – Canadian Association of Pharmaceutical Regulatory Affairs  
**CAR** – Chimeric antigen receptor  
**CARPHA** – The Caribbean Public Health Agency  
**CAS** – Central alerting system (UK) – **but also:**  
**CAS** – Chemical abstract systems  
**CAT** – Committee for Advanced Therapies (EMA)  
**CATMP** – Combined Advanced Therapy Medicinal Product  
**CAVDRI** – Collaboration agreement between veterinary drug registration institutions  
**CAVOMP** – Clinical added value orphan medicinal product  
**CBER** – Center for Biologics Evaluation and Research (US FDA)  
**CBG/MEB** – Medicines Evaluation Board (the Netherlands)  
**CBP** – Corticoid binding protein  
**CC** – Candidate country (EU)  
**CCDP** – Complete clinical data package  
**CCDS** – Company core data sheet  
**CCG** – Clinical Commissioning Group (UK NHS)  
**CCG IAC** – Clinical Commissioning Group Indicator Advisory Committee  
**CGTPs** – Cell and gene therapy products  
**CCI** – Commercially confidential information  
**CCSI** – Company core safety information  
**CD** – Caesarean derived – **but also:**  
**CD** – Controlled drug  
**CDC** – Centers for Disease Control and Prevention (US)  
**CDDD** – Clinical dossier of drug development (Brazil)  
**CDEC** – Canadian Drug Expert Committee (Canada)  
**CDER** – Center for Drug Evaluation and Research (US FDA)  
**CDISC** – Clinical Data Interchange Standards Consortium  
**CDMA** – Canadian Drug Manufacturers Association  
**CDR** – Common Drug Review (Canada)  
**CDRH** – Center for Devices and Radiological Health (US FDA)  
**CDS** – Clinical decision support  
**CDSCO** – Central Drug Standard Organization (India’s clinical trials licensing authority)  
**CDSM** – Committee on Dental and Surgical Materials (UK)  
**CDx** – Companion Diagnostics

**CE Mark** – Conformité European (approval for EU medical devices)  
**CEA** – Cost-effectiveness analysis  
**CEC** – Central ethics committee – **but also:**  
**CEC** – Commission of the European Communities  
**CED** – Coverage with evidence development  
**CEE** – Central and Eastern Europe  
**CEEC** – Central and Eastern European Countries  
**CEFTA** – Central Europe Free Trade Area  
**CEN** – Comité Européen des Normes – European Committee for Standardization  
**CEP** – Central enquiry point (MHRA) – **but also:**  
**CEP** – Certificate of European Pharmacopoeia (aka Certificate of Suitability)  
**CER** – Clinical evaluation report – **but also:**  
**CER** – Comparative effectiveness research **CESP** – Common European submission portal  
**CF** – Cystic fibrosis  
**CFC** – Chlorofluorocarbons  
**CFDA** – China Food and Drug Administration (formerly State FDA – **SFDA**)  
**CFR** – Code of Federal Regulations (US)  
**CFS** – Certificate of Free Sale  
**CFSAN** – Center for Food Safety and Applied Nutrition (US)  
**cGLP** – Current good laboratory practice  
**cGMP** – Current good manufacturing practice  
**CGP** – Clinical Guidance Panel (Canada)  
**CH** – Clinical hold  
**CHAI** – Commission for Healthcare Audit and Inspection (UK)  
**CHC** – Consumer healthcare  
**CHMB** – Creatine kinase Muscle Brain  
**CHMP** – Committee for Medicinal Products for Human Use (EMA)  
CHMP – Committee for Medicinal Products for Human Use (previously: CPMP)  
**CHO** – Chinese hamster ovary cells  
**CHPA** – Consumer Healthcare Products Association  
**CI** – Confidence Interval, **and also:**  
**CI** – Contraindication  
**CIA** – Corporate Integrity Agreement (US)  
**CIOMS** – Council for International Organizations of Medical Sciences (WHO)  
**CIRS** – Centre for Innovation in Regulatory Science  
**CIS (countries)** – Commonwealth of Independent States (members are former Soviet Republic countries, currently including Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Uzbekistan, Turkmenistan, Ukraine)  
**CK** – Creatine kinase  
**Cl** – Total body clearance  
**Class Im** – Class I with measuring function (medical devices)  
**CLIA** – Clinical Laboratory Improvement Amendments (US)  
**CLL** – Chronic lymphocytic leukaemia  
**CLO** – Clinical overview  
**CLP** – Classification, labelling and packaging (medical devices)  
**CLS** – Clinical summary  
**C<sub>m</sub> or C<sub>max</sub>** – Maximum plasma concentration at steady state  
**CMA** – Conditional marketing authorisation (US)  
**CMC** – Chemistry, manufacturing, and controls  
**CMDCAS** – Canadian Medical Devices Conformity Assessment System  
**CMDh** – Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (EMA)  
**CMDR** – Canadian Medical Device Regulation  
**CMDv** – Co-ordination Group for Mutual Recognition and Decentralised Procedures – Veterinary (EMA)  
**CMN** – Comité de Moléculas Nuevas” (New Molecules Committee) (Mexico)  
**CMP** – Certificate of Medicinal Product – **but also:**  
**CMP** – Common product model  
**CMR** – Carcinogenic, mutagenic or reprotoxic [toxic to reproduction] – **but also:**  
**CMR** – Centre for Medicines Research  
**CMS** – Concerned member state (EU)  
**CMT** – Convergent medical technologies  
**COA/CofA** – Certificate of analysis

**CoAg** – Cooperative Agreement  
**COE** – Council of Europe  
**COMET** – Core Outcome Measures in Effectiveness Trials  
**COMP** – Committee for Orphan Medicinal Products (EMA)  
**COREPER** – Committee of Permanent Representatives to the Community  
**COSHH** – Control of Substances Hazardous to Health  
**COSTART** – Coding Symbols for a Thesaurus of Adverse Reaction Terms  
**CoU** – Context of Use  
**CP** – Centralised procedure (EU) – **but also:**  
**CP** – Comparability protocol (US)  
**CPAC** – Central Pharmaceutical Affairs Council (Japan)  
**CPC** – Combination Products Coalition  
**CPD** – Continuing professional development  
**CPI** – Critical Path Initiative (US)  
**CPMP** – Committee for Proprietary Medicinal Products (EMA)  
**CPP** – Certificate of pharmaceutical product – **but also:**  
**CPP** – Critical process parameter  
**CPQ** – Costs per quality-adjusted life year  
**CPR** – Cosmetic Products Regulation  
**CPRD** – Clinical Practice Research Datalink (MHRA)  
**CPS** – Chemistry – Pharmacy and Standards Subcommittee of the CSM (UK) – **but also:**  
**CPS** – Clinical performance study  
**CPSP** – Clinical performance study plan  
**CPU** – Clinical pharmacology unit  
**CPWP** – Cell-based Products Working Party (EMA)  
**CQA** – Clinical quality assurance – **but also:**  
**CQA** – Critical quality attribute  
**CR** – Computed radiology – **but also:**  
**CR** – Controlled release  
**CRF** – Case report form  
**CRG** – Clinical reference group (UK)  
**CRO** – Clinical Research Organisation  
**CRP** – Canadian reference product (WHO) – **but also:**  
**CRP** – Collaborative registration procedure  
**CRS** – The Caribbean Regulatory System – **but also:**  
**CRS** – Cytokine release syndrome  
**CS** – Clinically significant – **but also:**  
**CS** – Common specifications  
**CSA** – Controlled Substances Act **CSI** – Core safety information  
**CSM** – Centralised statistical monitoring – **but also:**  
**CSM** – Committee on Safety of Medicines (UK)  
**CSO** – Consumer Safety Officer (US)  
**CSP** – Core safety profile  
**CSR** – Clinical study report (EU)  
**CSV** – Comma-separated values  
**CT** – Clinical trial – **but also:**  
**CT** – Computed tomography  
**CTA** – Clinical trial application – **but also:**  
**CTA** – Clinical trial assay – **and also:**  
**CTA** – Clinical trial authorisation  
**CTAG** – Clinical Trials Action Group (Australia) – **but also:**  
**CTAG** – Clinical Trials Coordination and Advisory Group  
**CTC** – Clinical trial certificate (Hong Kong, Singapore)  
**CTD** – Clinical Trials Directive – **but also:**  
**CTD** – Common technical document\* [\*Although 'dossier' has become commonplace – the correct term is 'document']  
**CTEG** – Clinical Trials Expert Group  
**CTFG** – Clinical Trials Facilitation Group  
**CTIS** – Clinical Trials Information System (*formerly the EU clinical trial portal and database, EudraCT*)  
**CTMP** – Cell therapy medicinal product  
**CTMS** – Clinical trial management system

**CTN** – Clinical trial notification (Australia)  
**CTOC** – Comprehensive Table of Contents Headings and Hierarchy  
**CTR** – Clinical Trial Regulation  
**CTS** – Common technical specification – **but also:**  
**CTS** – Communication Tracking System (*formerly Eudratrack*)  
**CTTI** – Clinical Trials Transformation Initiative  
**CTU** – Clinical trials unit  
**CTX** – Clinical trial exemption (UK)  
**CUA** – Cost utility analysis  
**CUP** – Compassionate use programme  
**CV** – Controlled vocabulary  
**CVM** – Center for Veterinary Medicine (US)  
**CVMP** – Committee for Medicinal Products for Veterinary Use (EMA)  
**CVO** – Chief Veterinary Officer  
**CVS** – Cardiovascular system  
**CVZ** – Dutch Health Care Insurance Board  
**CWoW** – Combined Ways of Working  
**CZ** – Climatic zone

#### **DDD**

**DAB** – German Pharmacopoeia (Deutsches Arznei Buch)  
**DAC** – Data analysis centre  
**DACS** – Detailed and critical summary  
**DAE** – Discontinuation due to an adverse event  
**DAL** – Defect action level (US)  
**DAMOS** – Drug application methodology with optical storage  
**DB** – Device Bulletin (MHRA)  
**DCGI** – Drugs Controller General of India  
**DCGI** – India's regulatory authority (Directorate General of Health Services in the Ministry of Health and Family Welfare)  
**DCP** – Decentralised procedure (EU)  
**DCTs** – Decentralised clinical trials  
**DD** – District Director (US)  
**DDC(P)** – Drug-device combination (product)  
**DDD** – Defined daily dose  
**DDMAC** – Division of Drug Marketing, Advertising and Communications (CDER)  
**DDPS** – Detailed description of pharmacovigilance system  
**DDX** – Doctors' and dentists' exemption (UK)  
**DE** – Designated examination  
**DEA** – Drug Enforcement Agency (US)  
**DEREK** – Deductive estimate of risk from existing knowledge  
**DES** – Data exchange standard (EU) – **but also:**  
**DES** – Drug eluting stent  
**DESI** – Drug efficacy study implementation (US)  
**DG** – Directorate-General (at the European Commission)  
**DGEM** – Disease-gene expression matching  
**DGV** – Direcção Geral de Veterinária (Veterinary Medicines Agency) (Portugal)  
**DH** – Department of Health (UK)  
**DHHS** – Department of Health and Human Services (US)  
**DHPC** – Direct healthcare professional communication (formerly 'Dear Doctor Letter')  
**DIA** – Drug Information Association (US)  
**DIBD** – Development international birth date  
**DID** – Design inputs document  
**DIMDI** – Deutsches Institut für Medizinische Dokumentation und Information (Germany)  
**DKMA** – Lægemiddelstyrelsen/Danish Medicines Agency (Denmark)  
**DLP** – Data lock point  
**DMF** – Drug master file  
**DMPK** – Drug metabolism and pharmacokinetics  
**DMRC** – Defective Medicines Report Centre (MHRA)  
**DMS** – Document management system  
**DMT** – Disease modifying therapy

**DOE** – Design of experiments  
**DoR** – Duration of Response  
**DP** – Drug product  
**DPI** – Dry powder inhaler  
**DPR** – Dual Pack import Registration  
**DR** – Deliberate release – **but also:**  
**DR** – Digital radiology  
**DRA** – Drug Regulatory Authority  
**DRF(S)** – Dose range finding (study)  
**DRMP** – Developmental risk management plan  
**DRR** – Durable response rate  
**DS** – Drug substance  
**DSC** – Differential scanning calorimetry  
**DSMC** – Data safety monitoring committee  
**DSRU** – Drug Safety Research Unit (EMA)  
**DSUR** – Development safety update report  
**DTaP** – Diphtheria, tetanus and pertussis  
**DTC** – Direct-to-consumer  
**DTD** – Document type definition  
**DUNS** – Data universal numbering system  
**DUS** – Drug utilisation study  
**DVPHNFS** – Department for Veterinary Public Health, Nutrition and Food Safety (Italy)  
**DWH** – Data warehouse  
**Dx** – Diagnostic

**EEE**  
**EA** – Environmental assessment  
**EAC** – East African Community  
**eAF** – electronic Application Form  
**EAI** – Estimated acute intake  
**EAMS** – Early Access to Medicines Scheme (UK)  
**EBE** – European Biopharmaceutical Enterprises  
**EbM** – Evidence-based medicine  
**EC** – Ethics committee – **but also:**  
**EC** – European Commission – **and also:**  
**EC** – Exceptional circumstances  
**ECDC** – European Centre for Disease Prevention and Control  
**ECG** – Electrocardiogram  
**ECHAMP** – European Coalition on Homoeopathic and Anthroposophic Medicinal Products  
**ECHR** – European Court of Human Rights  
**ECJ** – European Court of Justice  
**ECPHIN** – European Community Pharmaceutical Information Network  
**ECRAB** – European Committee on Regulatory Aspects of Biotechnology (EBCG)  
**eCRF** – electronic case report form  
**eCTD** – electronic common technical document [not dossier\*] \*Although 'dossier' has become commonplace – the correct term is 'document'  
**ED** – Early dialogue  
**EDA** – Egyptian Drug Authority  
**EDC** – electronic data capture  
**EDMF** – European drug master file  
**eDMS** – electronic document management system  
**EDQM** – European Directorate for the Quality of Medicines EDQM – European Directorate for the Quality of Medicines |  
**EDT** – Electronic data transfer  
**ED<sub>x</sub>** – Effective dose at X%  
**EEA** – European Economic Area (comprising the EU countries, plus Iceland, Liechtenstein and Norway)  
**EEC** – European Economic Community  
**EEG** – Electroencephalogram  
**eERA** – extended Environmental Risk Assessment  
**EEU** – Eurasian Economic Union  
**EFA** – European Federation of Allergy and Airways Diseases Patients' Associations



**EFPIA** – European Federation of Pharmaceutical Industries and Associations (<http://www.efpia.eu>)  
**EFPIA** – European Federation of Pharmaceutical Industries and Associations  
**EFQM** – European Foundation for Quality Management  
**EFSA** – European Food Safety Authority  
**EFTA** – European Free Trade Association  
**EGA** – European Generic medicines Association – **Name changed 10 March 2016 to “Medicines for Europe”**  
**EGGVP** – European Group for Generic Veterinary Products  
**EGP** – Economic Guidance Panel (Canada)  
**EHR** – Electronic healthcare record  
**EIA** – Environmental Impact Assessment  
**EINECS** – European Inventory of Existing Chemical Substances  
**ELA** – Establishment license application (US)  
**EMA** – European Medicines Agency (formerly European Medicines Evaluation Agency – **EMEA**)  
**EMACOLEX** – European Medicines Agencies Co-operation of Legal and Legislative Issues  
**EMCDDA** – European Monitoring Centre for Drugs and Drug Addiction  
**EMEA** – Europe, Middle East & Africa  
**EMEA** – see above – **but also:**  
**EMEA** – Europe, Middle East, Africa & Asia  
**EMR** – Electronic medical records  
**EMRC** – European Medical Research Councils (a unit of the **ESF** – see below)  
**EMVO** – European Medicines Verification Organisation  
**EMVS** – European Medicines Verification System  
**ENCePP** – European Network of Centres for Pharmacoepidemiology and Pharmacovigilance  
**eNDA** – Electronic New Drug Application  
**ENP** – European Neighborhood Policy  
**Enpr-EMA** – European Network of Paediatric Research at the European Medicines Agency  
**ENS** – Early notification system  
**EOF** – Ethnikos Organismos Farmakon – aka National Organization for Medicines (Greece’s regulatory agency)  
**EoP** – End of Procedure  
**EOP1** – End of Phase 1 (US)  
**EOP2** – End of Phase 2 (US)  
**EOQ** – European Organization for Quality  
**EP** – European Parliament – **but also:**  
**EP/Ph Eur** – European Pharmacopoeia (aka Pharm Eur)  
**EPA** – Environmental Protection Agency (US) and (Ireland)  
**EPAA** – European Partnership for Alternative approaches to Animal testing  
**EPAD** – European Prevention of Alzheimer’s Dementia  
**EPADES** – European Parliament Document Exchange Server  
**EPAR** – European public assessment report  
**EPC** – European Pharmacopoeia Commission  
**EPHA** – European Public Health Alliance  
**ePI** – Electronic product information  
**EPI** – Essential Program for Immunisation  
**EPID** – Extended (also Expanded) Public Information Document  
**EPITT** – European Pharmacovigilance Issues Tracking Tool  
**EPL** – Effective patent life  
**EPO** – European Patent Office  
**EPPOSI** – European Platform for Patients’ Organisation – Science & Industry  
**EPPV** – Early post-marketing phase vigilance (eg, in Japan)  
**EPRG** – European Pharmacovigilance Research Group  
**EPRUMA** – European Platform for the Responsible Use of Medicines in Agriculture  
**EPS** – Eco-Pharmaco-Stewardship  
**ePSUR** – electronic periodic safety update report  
**EQM** – Equivalence margin  
**ERs** – Essential requirements (devices)  
**ERA** – Environmental risk assessment – **but also:**  
**ERA** – European regulatory affairs  
**ERB** – Ethical review board  
**eRMR** – electronic Reaction Monitoring Report  
**ERMS** – European risk management strategy  
**ERMS-FG** – European Risk Management Strategy Facilitation Group (HMA)  
**ERP** – European Reference Medicinal Product

**ESF** – European Science Foundation  
**ESG** – Electronic submissions gateway (FDA)  
**ESM** – European stakeholder model  
**ESPAR** – Executive Summary Pharmacovigilance Assessment Report (EU)  
**ESR** – Erythrocyte Sedimentation Rate  
**ESRA** – European Society of Regulatory Affairs  
**ESTRI** – Electronic Standards for the Transfer of Regulatory Information  
**ESVAC** – European Surveillance of Veterinary Antimicrobial Consumption  
**ETASU** – Elements to ensure safe use (US)  
**eTMF** – electronic Trial Master File  
**ETOMEP** – European Technical Office for Medical Products (within EMA)  
**EU** – European Union  
**EUS** – Group of countries comprising Germany, France, Italy, Spain and the UK  
**EUA** – Emergency use authorisation  
**EU-ADR** – Exploring and Understanding Adverse Drug Reactions by Integrative Mining of Clinical Records and Biomedical Knowledge (formerly known as ALERT) (EU)  
**EUBAN** – European Borderline Assessment Network  
**EU-IN** – EU Innovation Network  
**EUCERD** – EU Committee of Experts on Rare Diseases  
**EUCOMED** – European Confederation of Medical Device Associations  
**EUAMED** – European Databank on Medical Devices  
**EUDRA** – European Union Drug Regulatory Authorities  
**EudraCT** – European Union Drug Regulatory Authorities Clinical Trials database  
**EudraNet** – European Union Drug Regulatory Authorities Network  
**EudraSmPC** – Summary of Product Characteristics  
**EUnetHTA** – European Network for Health Technology Assessment  
**EU-NTC** – EU Network Training Centre  
**EUPATI** – European Patients’ Academy on Therapeutic Innovation  
**EUPD** – EU Portal and Database  
**EuPFI** – European Paediatric Formulation Initiative  
**EURD** – European Union reference date  
**EUREC** – European Network of Research Ethics Committees  
**EURL** – EU reference laboratory  
**EUR-OP** – EU Office for Publications  
**EUTCT** – European Union Telematics Controlled Terms  
**EUTMB** – EU Telematics Management Board  
**EV – EudraVigilance** – European Union Drug Regulating Authorities Pharmacovigilance  
**EVCTM** – EudraVigilance Clinical Trial Module  
**EV-EWG** – EudraVigilance Expert Working Group  
**EVIDENT** – Evidence Database on New Technologies  
**EVM** – European Vaccine Manufacturers  
**EVMPD** – EudraVigilance medicinal products dictionary  
**EVPM** – EudraVigilance post-authorisation module  
**EVPRM** – EudraVigilance product report message  
**EWG** – Expert Working Group  
**EWP** – Efficacy Working Party (EMA)

#### **FFF**

**FACC** – Food Additives and Contaminants Committee (UK)  
**FAGG** – Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten (Belgium)  
**FAIR (data)** – Findable, accessible, interoperable and reusable (data)  
**FAMHP** – Federal Agency for Medicines and Healthcare Products (Belgium)  
**FAR** – Final assessment report  
**Farmindustria** – Association of Italian Pharmaceutical Manufacturers (Italy)  
**FCC** – Food and Chemical Codex  
**FDA** – Food and Drug Administration (the US regulatory authority)  
**FDAAA** – FDA Amendments Act  
**FDAMA** – FDA Modernization Act  
**FDASIA** – Food and Drug Administration Safety and Innovation Act  
**FDC** – Fixed dose combination  
**FDC Act** – Food – Drug and Cosmetic Act (US)  
**FIH** – First-in-human (aka **FIM** – first-in-man; and **FTIM** – first-time-in-human)

**FIM** – First-in-man  
**FIM-A** – Federal Institute for Medicines (Austria)  
**FIMEA** – Finnish Medicines Agency (Finland)  
**FIP** – International Pharmaceutical Federation  
**FMD** – Falsified Medicines Directive (EU)  
**FMEA** – Failure mode and effect analysis  
**FMECA** – Failure Modes Effects and Criticality Assessment  
**FNOM-CeO** – Federazione Nazionale degli Ordini dei Medici-Chirurghi e degli Odontoiatri (IT) = Italian organisation of doctors and dentists  
**FOB** – Follow-on biologic  
**FOFI** – Federazione Ordini Farmacisti Italiani (IT) = Italian Organisation of Pharmacists  
**FOI Act** – Freedom of Information Act (US)  
**FOM** – Francophone Overseas Markets  
**FONSI** – Finding of no significant impact  
**FOP** – Follow-on protein  
**FPA** – Food producing animal  
**FPFV** – First patient first visit  
**FPIF** – Finnish Pharmaceutical Industry Association  
**FPP** – Finished pharmaceutical product  
**FPRC** – Final product release control  
**FPRR** – Final product release responsibility  
**FQA** – Full quality assurance  
**FR** – Federal Register (US)  
**FRPs** – Facilitated regulatory pathways  
**FrP** – French Pharmacopoeia (Pharmacopée Française, aka **PF**)  
**FSCA** – Field safety corrective action (medical devices sector)  
**FSIS** – Food Safety and Inspection Service (US)  
**FSN** – Field safety notice (medical devices)  
**FTA** – Fault tree analysis  
**FTC** – Federal Trade Commission (US)  
**FTD** – Fast track designation (US)  
**FTE** – Full Time Equivalent (employee)  
**FTIM** – First-time-in-human  
**FTIR** – Fourier Transform infra-red  
**FU** – Farmacopea Ufficiale – the Italian Pharmacopoeia  
**FUM** – Follow-up measures  
**FVAR** – Final Variation Assessment Report  
**FY** – Fiscal year

**GGG**

**GAIN Act** – Generating Antibiotic Incentives Now Act (US)  
**GATT** – General Agreement on Tariffs and Trade  
**GCC (region)** – Gulf Cooperation Council (region)  
**GCC-DR** – Gulf Central Committee for Drug Registration  
**GCD** – Global clinical development  
**GCG** – Global Cooperation Group (ICH)  
**GCP** – Good clinical practice  
**GCPv** – Good Clinical Practice (Veterinary)  
**GDP** – Good distribution practice  
**GDPR** – General Data Protection Regulation  
**GDUFA** – Generic Drug User Fee Amendments (FDA)  
**GEG** – Geriatrics Expert Group  
**GEP** – Good epidemiological practice  
**GGP** – Good guidance practice  
**GHTF** – Global Harmonisation Task Force  
**GIVIMP** – Good *in vitro* method practices  
**GLC** – Gas liquid chromatography  
**GLP** – Good laboratory practice  
**GLPMA** – Good Laboratory Practice Monitoring Authority (UK)  
**GMA** – Global marketing authorisation  
**GMC** – General Medical Council (UK)  
**GMDN** – Global medical device nomenclature (medical devices sector)

**GMiA** – Generic Medicines industry Association (Australia)  
**GMO** – Genetically modified organism  
**GMP** – Good management practice  
**GMP** – Good manufacturing practice – **but also:**  
**GNA** – Grounds for non-acceptance  
**GPAG** – Granularity and Periodicity Advisory Group  
**GPhP** – Good Pharmacopoeial Practices  
**GPIA** – Generic Pharmaceutical Industry Association (US)  
**GPMSp** – Good postmarketing surveillance practice (Japan)  
**GPP** – Good paediatric practice – **but also:**  
**GPP** – Good pharmacoepidemiology practice  
**GPP2** – Good publication practice  
**GPSP** – Good Post-marketing Study Practice  
**GpvP** – Good pharmacovigilance practice  
**GQCLP** – Good Quality Control Laboratory Practice  
**GQP** – Good quality practice  
**GRAS** – Generally Recognised as Safe (US)  
**GRB** – Global Regulatory Board  
**GRP** – Good regulatory practice – **but also:**  
**GRP** – Good review practice (US)  
**GSL** – General sales list  
**GSP** – Good statistics practice  
**GSPRs** – General Safety and Performance Requirements  
**GTI** – Genotoxic impurity  
**GTMP** – Gene therapy medicinal product  
**GTP** – Gene therapy product  
**GTWP** – Gene Therapy Working Party  
**GVD** – Global value dossier  
**GvHD** – Graft versus Host Disease  
**GVP** – Good pharmacovigilance practice  
**GxP** – general term for “good practice” quality guidelines and regulations, where “x” is the symbol for the variable descriptor

#### **HHH**

**HA** – Health authority  
**HACCP** – Hazard analysis critical control point (inspection technique) (US)  
**HAI** – Health Action International  
**HAS** – Haute Autorité de santé (French health authority)  
**Hb** – Haemoglobin  
**HBD** – Harmonised Birth Date  
**HCD** – Historical control data  
**HCP** – Healthcare professional  
**HCPWP** – Healthcare Professionals Working Party (EMA)  
**HCR** – Holder of certificate of registration (South Africa)  
**HCRW** – Health and Care Research (Wales)  
**HCT** – Haematocrit  
**HDE** – Humanitarian device exemption  
**HDI** – Human development index  
**HE** – Hospital exemption  
**HEOR** – Health economics and outcomes research  
**HEW** – Health, Education and Welfare (US)  
**HFE** – Human factors engineering  
**HGAC** – Human Genetics Advisory Committee  
**HGPRT** – Hypoxanthine-guanine-phosphoribosyltransferase activity  
**HHMG** – Human Harmonisation Maintenance Group  
**HHS** – US Department of Health and Human Services  
**HIC** – High income countries

#### **c**

**HIMA** – Health Industry Manufacturers Association (US)  
**HL7** – Health Level Seven  
**HLGT** – High level group term (in MedDRA)  
**HLT** – High level term (in MedDRA)

**HMA** – Heads of Medicines Agencies (Human and Veterinary) (EU)  
**HMO** – Health Maintenance Organisation (US)  
**HMPC** – Committee on Herbal Medicinal Products (EMA)  
**HMR** – Human Medicines Regulations  
**HNSTD** – Highest Non Severely Toxic Dose  
**HoA** – Heads of Agencies  
**HPB** – Health Protection Board (Canada)  
**HPLC** – High performance liquid chromatography  
**HPRA** – Health Products Regulatory Authority (formerly Irish Medicines Board)  
**HR** – Heart rate  
**HRA** – Health Research Authority (UK)  
**HRB** – Health Research Board  
**HREC** – Human Research Ethics Committee  
**HRQoL** – Health-related quality of life  
**HRT** – Hormone replacement therapy  
**HSA** – Human serum albumin  
**HSC** – Haematopoietic stem cells  
**HSE** – Health and Safety Executive (UK)  
**HST** – Highly specialised technologies  
**HTA** – Health technology assessment  
**HTS** – High-throughput screening  
**HV** – Healthy volunteer

### **III**

**I&AC** – Imaging and acute care (medical devices sector)  
**IAM** – Identity and Access Management  
**IAPO** – International Alliance of Patients' Organisations  
**IB** – Investigator's brochure  
**IBD** – International Birth Date  
**IBMS** – Institute of Basic Medical Sciences (China)  
**IC** – Informed consent  
**ICD** – Informed consent document – **but also:**  
**ICD** – International Classification of Diseases  
**ICDRA** – International Conference of Drug Regulatory Authorities  
**ICER** – Incremental cost-effectiveness ratio  
**ICF** – Informed consent form  
**ICH** – International Council for Harmonisation (formerly International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use)  
**ICI** – Immune checkpoint inhibitor  
**ICMJE** – International Committee of Medical Journal Editors  
**ICMRA** – International Coalition of Medical Regulatory Authorities  
**ICP-MS** – Inductively coupled plasma mass spectrometry  
**ICSR** – Individual case safety report  
**ICT** – Information and communications technology  
**ICTRP** – International Clinical Trials Registry Platform (WHO)  
**IC<sub>x</sub>** – Inhibition concentration at X%  
**IDE** – Investigational Device Exemption  
**IDMP** – Identification of medicinal products – **but also:**  
**IDMP** – Infectious diseases management program (US)  
**IDR** – Idiosyncratic drug reaction  
**IDRAC** – International Drug Registration Assisted by Computer  
**IEC** – Independent ethics committee  
**IFAH** – International Federation for Animal Health  
**IFPMA** – International Federation of Pharmaceutical Manufacturers and Associations  
**IFU** – Instructions for use  
**IGDG** – Informal Generic drug Discussion Group  
**IGDRP** – International Generic Drug Regulators Pilot  
**IGPA** – International Generic Pharmaceutical Alliance  
**IGZ** – the Netherlands Healthcare Inspectorate  
**IIG** – Inactive ingredient guide (US FDA)  
**IIS** – Investigator initiated study

**IM** – Intramuscular – **but also:**  
**IM** – Issue management  
**IM(ER)R** – Ionising radiation (medical exposure) regulations  
**IMA** – Lyfjastofnun/Icelandic Medicines Agency (Iceland)  
**IMB** – Irish Medicines Board [name changed in July 2014 to **HPRA** – Health Products Regulatory Authority]  
**IMCA** – Lyfjastofnun/Icelandic Medicines Control Agency (Iceland)  
**IMD** – Implantable medical device  
**IMDA** – Irish Medical Device Association  
**IMDRF** – International Medical Device Regulators Forum  
**IME** – Important medical event  
**IMI** – Innovative Medicines Initiative  
**IMM** – Irreversible morbidity or mortality  
**IMP** – Investigational medicinal product  
**ImPACT** – Imaging performance assessment of CT scanner  
**IMPD** – Investigational medicinal product dossier  
**IMRDF** – International Medical Device Regulatory Forum  
**IMS** – Information management strategy  
**INADA** – Investigational new animal drug application  
**IND** – Investigational new drug (US)  
**INDA** – Investigational new drug application (US)  
**INDC** – Investigational New Drug Committee  
**INFARMED** – Instituto Nacional da Farmacia e do Medicamento (Portugal’s regulatory agency)  
**INN** – International nonproprietary name  
**IO** – Immune-oncology  
**IP** – Intellectual property – **but also:**  
**IP** – Interested Parties – **and also:**  
**IP** – Intraperitoneal  
**IPAC** – International Pharmaceutical Aerosol Consortium  
**IPC** – International Pharmaceuticals Council  
**IPCs** – In-process controls  
**IPD** – Individual Patient Data  
**IPEC** – International Pharmaceutical Excipients Council  
**IPI** – International Pricing Index  
**iPiE** – Intelligence-led assessment of Pharmaceuticals in the Environment  
**IPO** – Intellectual Property Office  
**IPR** – Intellectual property rights  
**IPRF** – International Pharmaceutical Regulators Forum  
**iPSP** – initial Paediatric Study Plan  
**IPU** – Irish Pharmaceutical Union  
**IQM** – Integrated quality management  
**IR** – Infra-red – **but also:**  
**IR** (tablets) – Immediate release  
**IRAS** – Integrated Research Application System  
**IRB** – Institutional review board (aka Independent Ethics Committee (**IEC**) or Ethical Review Board (**ERB**))  
**IRC** – Institutes Review Committee  
**IRD** – International registration document  
**IRDiRC** – International Rare Diseases Research Consortium  
**IRN** – Incident Review Network  
**IRP** – Independent review panel  
**IRR** – Ionising radiation regulation  
**IRT** – Interactive response technology – **but also:**  
**IRT** – Interdisciplinary Review Team (US)  
**IS** – Information science/systems – **but also:**  
**IS** – Internal standard  
**ISCT** – In silico clinical trial  
**ISE** – Integrated summary of efficacy  
**ISO** – International Standards Organisation  
**ISRB** – Integrated summary of risk benefit  
**ISS** – Integrated summary of safety  
**IT** – Information technology  
**ITF** – Innovation Task Force (EMA)  
**ITT** – Intent-to-treat

**IU** – International unit  
**IUPAC** – International Union of Pure and Applied Chemistry  
**IV** – Intravenous  
**IVD** – *in vitro* (medical) device; **but also:**  
**IVD** – *in vitro* diagnostics  
**IVDR** – In Vitro Diagnostic Regulation  
**IVIVC** – *in vitro in vivo* correlation  
**IVMP** – Immunological veterinary medicinal product  
**IVRS** – Interactive voice response system  
**IWG** – Implementation working group  
**IWP** – Immunologicals Working Party (EMA)

### **JJJ**

**JAN** – Japanese Approved Name  
**JAZMP** – Javna agencija Republike Slovenije za zdravila in medicinske pripomočke (Slovenia's regulatory agency)  
**JFDA** – Jordan Food & Drug Administration  
**JIACRA** – Joint Interagency Antimicrobial Consumption and Resistance Analysis  
**JNDA** – Japanese New Drug Application  
**JP** – Japanese Pharmacopoeia  
**JPMA** – Japan Pharmaceutical Manufacturers Association  
**J-RMP** – Japanese risk management plan (template)

### **KKK**

**KAS** – Known active substance  
**KFDA** – Korean Food and Drug Administration  
**KIT** – Key intelligence topic  
**KM** – Knowledge management  
**KOL** – Key opinion leader  
**KOM** – Kick-off meeting

### **LLL**

**LABST** – Laboratory animal batch safety testing  
**LAT** – Light authoring tool (EU)  
**LCM** – Lifecycle management  
**LD<sub>50</sub>** – Lethal dose required to kill 50% of the study population  
**LDH** – Lactate dehydrogenase  
**LEC** – Local ethics committee  
**LED** – Least Effect Dose  
**LEEM** – Les Entreprises du Médicament (French Pharmaceutical Industry Association)  
**LFT** – Liver function test  
**LiCT** – Low-intervention clinical trial  
**LIF** – Läkemedelsindustriföreningen (Swedish Pharmaceutical Industry Association)  
**LLL** – Lifelong learning  
**LM** – Limited markets (veterinary)  
**LMA** – Limited marketing authorisation  
**LMICs** – Low and middle income countries  
**LOD** – Loss on drying  
**LOI** – Letter of intent (US)  
**LoNR** – Letter of non-repudiation agreement (FDA)  
**LoOI** – List of Outstanding Issues  
**LoQ** – List of Questions  
**LPLV** – Last patient last visit  
**LSIF** – Life Sciences Innovation Forum  
**LT** (stability) – Long term  
**LTT** – Lines to take [document usually not for publication] (EMA)  
**LVP** – Large volume parenterals

### **MMM**

**M&S** – Modelling and simulation  
**MA** – Marketing authorisation  
**MAA** – Marketing authorisation application (EU)

**MABEL** – Minimal anticipated biological effect level  
**MAD** – Multiple ascending dose (study), but **also:**  
**MAD** – Mutual acceptance of data (OECD Council Decision)  
**MAFF** – Ministry of Agriculture, Forestry and Fisheries (Japan)  
**MAH** – Marketing authorisation holder  
**MAID** – Manufacturers, authorised representatives, importers and distributors  
**MALAM** – Medical Lobby for Appropriate Marketing  
**Mane** – Morning  
**MANSEV** – Marketing Authorisation by Network Submission and Evaluation  
**MAPPs** – Medicines adaptive pathways to patients  
**MAUDE** – Manufacturer and User Facility Device Experience (US)  
**MAWP** – Multi-Annual Work Plan (HMA)  
**MaxSPRT** – Maximised sequential probability ratio test  
**MB** – Management Board  
**MCC** – Medicines Control Council (South Africa)  
**MCDA** – Multi-criteria decision analysis  
**MCH** – Mean cell haemoglobin concentration  
**MCPC** – Major contribution to patient care  
**MCV** – Mean cell volume  
**MD** – Medical device  
**MDA** – Medical device alert  
**MDCG** – Medical Device Coordination Group  
**MDD** – Medical Device Directive – **but also:**  
**MDD** – Medical Devices Directorate  
**MDDS** – Medical device data systems  
**MDEG** – Medical Devices Expert Group  
**MDEG-BC** – Medical Devices Expert Group on Borderline and Classification  
**MDI** – Metered dose inhaler  
**MDLO** – Medical Device Liaison Officer  
**MDR** – Medical Device Regulation – **but also:**  
**MDR** – Medical device reporting – **and also:**  
**MDR** – Multi-drug resistant  
**MDSAP** – Medical Device Single Audit Program (US, Canada)  
**MDV** – Medical device vigilance  
**MEB** – Medicines Evaluation Board (the Netherlands) – also known as Dutch College  
**MedDevs** – Guidances outlining the requirements of the Medical Device Directive  
**MedDRA** – Medical Dictionary for Regulatory Activities  
**MEDEV** – Medicine Evaluation Committee (EU)  
**MEDSAFE** – New Zealand Medicines and Medical Devices Safety Authority  
**MENA** – Middle East and North Africa  
**MERS** – Multi-agency electronic regulatory system  
**MFDS** – Ministry of Food and Drug Safety (Korea)  
**MgSzH** – Mezogazdasagi Szakigazgatasi Hivatal Directorate of Veterinary Medicinal Products (Hungary)  
**MHRA** – Medicines and Healthcare products Regulatory Agency  
**MHW** – Ministry of Health and Welfare (Japan)  
**MIA** – Manufacturing and Importation Authorisation  
**MIA(IMP)** – Manufacturer’s Authorisations for IMPs  
**MIDD** – Model-informed drug development (US)  
**MIMS** – Monthly Index of Medical Specialities (UK)  
**MINE** – Medicines Information Network for Europe  
**MIR** – Manufacturer incident report  
**MISG** – Ministerial industry strategy group  
**ML** – Machine learning – **but also:**  
**ML** – Manufacturer’s licence (UK)  
**MLD** – Minimal lethal dose  
**MLM** – Medical literature monitoring  
**MMA** – Malta Medicines Authority – **but also:**  
**MMA** – Mobile medical app  
**MNAT** – Multinational Assessment Team  
**MO** – Major Objection  
**MoA** – Mechanism of action – **but also:**  
**MOA** – Ministry of Agriculture



**MoCA** – Mechanism of Coordinated Access  
**MOD 1** – Module One (laboratory facility) (US)  
**MOD 2** – Module Two (laboratory facility) (US)  
**MORE** – Manufacture's Online Reporting Environment (MHRA) (medical devices sector)  
**mOS** – median Overall Survival  
**MOU** – Memorandum of Understanding  
**MPA** – Medical Products Agency – Sweden  
**MPD** – Medicinal Products Directive  
**MPID** – Medicinal product identifier  
**MQAS** – Model Quality Assurance System  
**MQSA** – Mammography Quality Standards Act of 1992 (US)  
**MR** – Mutual Recognition  
**MRA** – Mutual recognition agreement  
**MRAs** – Medicines regulatory authorities – **but also:**  
**MRC** – Medical Research Council  
**MRD** – Multiple rising dose  
**MRFG** – Mutual Recognition Facilitation Group (EMA)  
**MRH** – Medicines regulatory harmonisation  
**MRI (scan)** – Magnetic resonance imaging (scan) – **but also:**  
**MRI** – Mutual recognition information  
**MRL** – Maximum residue limit  
**MRP** – Mutual recognition procedure (EU)  
**MRSD** – Maximum recommended safe dose  
**MRU** – Medicines Regulatory Unit (Health Division Malta)  
**MS** – Mass spectrometry – **but also:**  
**MS** – Member state/s (EU)  
**MSWG** – Modelling and Simulation Working Group  
**MTD** – Maximum tolerated dose  
**MTS** – Medicines testing scheme (MHRA)  
**MUMS** – Minor use and minor species (veterinary)

**NNN**

**N&ET** – New and emerging technologies (see also: NET WG)  
**N-11** – Next 11 (group of countries comprising Bangladesh, Egypt, Indonesia, Iran, Korea, Mexico, Nigeria, Pakistan, Philippines, Turkey and Vietnam)  
**NAD** – No abnormality detected  
**NADA** – New animal drug application (US)  
**NAFDAC** – National Agency for Food and Drug Administration and Control (Nigeria)  
**NAFTA** – North American Free Trade Association (US)  
**NAI** – No action indicated  
**NAO** – National Audit Office (UK)  
**NAP** – Nationally authorised product  
**NAS** – New active substance  
**NB** – Notified body (EU)  
**NBE** – New biological entity  
**NBIC** – Nanotechnology, biotechnology, information science and cognitive science  
**NBO** – Notified body opinion  
**NBOG** – Notified Body Operations Group (EU)  
**NC3Rs** – National Centre for the Replacement, Refinement and Reduction of Animals in Research (UK)  
**NCA** – National competent authority  
**NCAS** – New chemical active substance  
**NCD** – Non-communicable diseases  
**NCE** – New chemical entity  
**NCI** – National Cancer Institute (US) – **but also:**  
**NCI** – National Coordinating Investigator  
**NCO** – Non clinical overview  
**NCS** – Non clinical summary  
**NCTR** – National Center for Toxicological Research (US)  
**NDA** – New drug application (US)  
**NDAC** – New Drug Advisory Committee (India)  
**NDMA** – Non-Prescription Drug Manufacturers Association (US)

**NDS** – New drug submission (Canada)  
**NED** – Non effect dose  
**NeeS** – Non eCTD electronic submission  
**NEFARMA** – Netherlands Pharmaceutical Industries Association  
**NET WG** – New & Emerging Technologies Working Group  
**NF** – National Formulary  
**NfG** – Note for Guidance (EU)  
**NGS** – Next generation sequencing  
**NHL** – non-Hodgkin's lymphoma  
**NHP** – Non-human primate  
**NHS** – National Health Service  
**NHV** – Normal healthy volunteer  
**NIAID** – National Institute of Allergy and Infectious Diseases  
**NIBSC** – National Institute for Biological Standards Control (UK)  
**NICE** – National Institute for Health and Care Excellence (formerly 'Clinical' Excellence)  
**NICHD** – National Institute of Child Health and Human Development (US)  
**NIH** – National Institutes of Health (US)  
**NIHR** – National Institute for Health Research (UK)  
**NIMP** – Non-investigational medicinal product (*but see AMP – Auxiliary medicinal product*)  
**NIR** – near infrared (spectroscopy) – **but also:**  
**NIR** – Non-interventional research  
**NIS** – Non-interventional study  
**NK cells** – Natural killer cells  
**NLEA** – Nutrition Labelling and Education Act of 1990 (US)  
**NLN** – Nordic Council on Medicines  
**NMA** – National Medicines Agency (Romania)  
**NMCA** – Norwegian Medicines Control Agency (aka **SLK**)  
**NME** – New molecular entity  
**NMFS** – National Marine Fisheries Service (US)  
**NMR** – Nuclear magnetic resonance  
**NMRAs** – National Medicines Regulatory Authorities  
**NMVO** – National Medicines Verification Organisation  
**NMVRVI** – Nacionalinis Maistro Ir Veterinarijos Rizikos Vertinimo Institutas (National Food and Veterinary Risk Assessment Institute) (Lithuania)  
**NOAEL** – No observable adverse effect level  
**NOAH** – National Office of Animal Health (UK)  
**NOAL** – No observed adverse effect level  
**NOC** – Notice of Compliance (Canada)  
**NOC/c** – Notice of Compliance with Conditions (Canada)  
**Nocte** – Night  
**NOEL** – No observable effect level  
**NoMA** – Norwegian Medicines Agency  
**NPCB** – National Pharmaceutical Control Bureau (Malaysia)  
**NPP** – Named patient product  
**NPRM** – Notice of Proposed Rulemaking  
**NPT** – Near-patient test  
**NRA** – National regulatory authority  
**NRG** – (invented) Name Review Group  
**NSA** – National Security Agency (US)  
**NSAID** – Nonsteroidal anti-inflammatory drug  
**NSB** – National Standards Body – **and also:**  
**NSB** – Non-similar biologic  
**NSCLC** – Non-small cell lung cancer  
**NSF** – No biologically significant finding (may be used in older reports)  
**NSN** – New substances notification (Canada)  
**NSR** – Non-significant risk  
**NSVA** – National Sanitary Veterinary Agency (Romania)  
**NtA** – Notice to applicants (EC)  
**NTD** – Neglected tropical disease  
**NTE** – No toxic effect level  
**NTI** – Narrow therapeutic index  
**NUI** – Non-urgent information (aka "Infifax") (EU)

**NWIP** – New work item proposal (EU)

**OOO**

**O/E** – Observed versus expected [analysis]

**oab** – On anhydrous basis

**oasfb** – On anhydrous solvent free basis

**OBL** – Own brand labelling

**OBP** – On-boarding partner

**OC** – Office of the Commissioner (US)

**OCA** – Office of Consumer Affairs (US)

**OCABR** – Official control authority batch release

**OCI** – Office of Criminal Investigation (US)

**OCF** – Office of Combination Products (US FDA)

**od** – once a day [*Latin: omne in die*] – but also:

**OD** – Orphan drug

**ODA** – Orphan Drugs Act (US)

**ODC** – Optimal diagnostic concentration (used on allergy products)

**ODD** – Orphan drug designation

**OE** – Oral explanation

**OECD** – Organisation for Economic Co-operation and Development

**OEI** – Official establishment inventory (US)

**OEM** – Original equipment manufacturer

**OES** – Original equipment supplier

**OGTR** – Office of the Gene Technology Regulator (Australia)

**OGYI/NIP** – National Institute of Pharmacy (Hungary)

**OH** – Oral Hearing

**OHDSI** – Observational Health Data Science and Informatics

**OIA** – Official action indicated

**OIE** – World Organisation for Animal Health

**OJ/OJEC** – Official Journal of the European Communities

**OLE (study)** – Open label extension (study)

**OMAR** – Orphan Maintenance Assessment Report

**OMCL** – Official Medicines Control Laboratories (part of **EDQM**)

**OMP** – Orphan medicinal product

**OMS** – Organisations data management service

**OOPD** – Office of Orphan Products Development (US FDA)

**OOS** – Out of specification

**OPA** – Office of Public Affairs (US)

**OPD** – Original pack dispensing

**OPDP** – Office of Prescription Drug Promotion (FDA's CDER)

**OPE** – Office of Planning and Evaluation (US)

**ORA** – Office of Regulatory Affairs (US FDA)

**ORGAM** – Organisational Matters

**ORR** – Overall response rate

**OS** – Overall survival

**OTC** – Over-the-counter

**PPP**

**P** – Pharmacy only (ie, medicinal product dispensed by a pharmacist)

**P to GSL** – Pharmacy to General Sales List

**P&L** – Packaging and labelling

**P&R** – Pricing and reimbursement

**PA** – Product authorisation – **but also:**

**PA** – Protocol assistance

**PAB** – Pharmaceutical Affairs Bureau (Japan)

**PAC-ATLS** – Post Approval Change – Analytical Testing Laboratory Site (US)

**PACMP** – Post-approval change management protocol

**PAD** – Pharmacologically active dose

**PaedPAR** – Paediatric Public Assessment Report

**PAES** – Post authorisation efficacy study

**PAGB** – Proprietary Association of Great Britain

**PAI** – Pre-approval inspection

**PAL** – Pharmaceutical Affairs Law (Japan)  
**PAM** – Patient activation measure (UK)  
**PAM(s)** – Post Authorisation Measure(s)  
**PAO** – Period after opening (cosmetic products)  
**PAR** – Preliminary assessment report  
**PAR** – Public Assessment report  
**PARENT** – Patient Registries Initiative (EU)  
**PAS** – Patient Affairs Staff, **and also:**  
**PAS** – Public Affairs Specialist (US)  
**PASS** – Post authorisation safety study  
**PAT** – Priority Action Team (EFPIA)  
**PAT** – Process analytical technology – **but also:**  
**PBAC** – Pharmaceutical Benefits Advisory Committee (Australia)  
**PBI** – Protein-bound iodine  
**BPBK** – Physiologically based pharmacokinetic modelling  
**PBRER** – Periodic benefit–risk evaluation report  
**PBS** – Pharmaceutical Benefit Scheme (Australia)  
**PBT** – Persistent, bioaccumulative and toxic (biocidal products)  
**PC** – Packaged commodities (India)  
**PCA** – Perception, cognition, action  
**PCG** – Product Coordination Group (EU)  
**PCID** – Package identifier  
**pCODR** – pan-Canadian Oncology Drug Review  
**PCORI** – Patient-Centered Outcomes Research Institute  
**PCPA** – Pan-Canadian Pricing Alliance  
**PCT** – Primary care trust (UK)  
**PCWP** – Patients’ and Consumers’ Working Party  
**PD** – Parallel distribution, **and also:**  
**PD** – Pharmacodynamics  
**PdAR** – Paediatric Assessment Report  
**PDCO** – Paediatric Committee (EMA)  
**PDE** – Permitted daily exposure  
**PDG** – Pharmacopoeial discussion group  
**PDMA** – Prescription Drug Marketing Act (US)  
**PDP** – Product development protocols (for medical devices) (US)  
**PDPs** – Product development partnerships  
**PDR** – Physician’s desk reference  
**PDS** – Public disclosure synopsis/system  
**PDUFA** – Prescription Drug User Fee Act (US)  
**PDX** – Patient-derived xenograft  
**PE** – Pharmacoeconomics  
**PEAG** – Pharmacovigilance Expert Advisory Group (MHRA)  
**PEC** – Patient Engagement Collaborative, **and also:**  
**PEC** – Predicted environmental concentration  
**PECA** – Protocol to the Europe Agreement on Conformity Assessment and Acceptance of industrial products  
**PED** – Patient experience data  
**PEFR** – Peak expiratory flow rate  
**PEFRAS** – Pan European Federation of Regulatory Affairs  
**PEI** – Paul-Ehrlich-Institut (Federal Institute for Vaccines and Biomedicines (one of the two German regulatory agencies)  
**PEM (study)** – Prescription-event monitoring (study)  
**PER** – Pharmaceutical evaluation report  
**PeRC** – Paediatric Review Committee (US)  
**PERF** – Pan European Regulatory Forum  
**PET/CT** – Positron emission tomography and computerised tomography  
**pfa (or b)** – pure free acid (or base)  
**PFDD** – Patient-focused drug development  
**PFI** – Pediatric Formulation Initiative (US)  
**PFMD** – Patient Focused Medicine Development  
**PFS** – Progression-free survival  
**PGD** – Patient group directions (written instructions)  
**PGENI** – Pharmacogenetics for Every Nation Initiative

**PGI** – Potentially genotoxic impurity  
**PgWP** – Pharmacogenomics Working Party  
**PGx** – Pharmacogenomics  
**Ph Eur** – European Pharmacopoeia  
**PHA** – Preliminary hazard analysis  
**PHARE** – Poland and Hungary; aid of the Restructure of the Economy; Now the Phare programme is one of the three pre-accession instruments financed by the European Communities to assist the applicant countries of central Europe in their preparations for joining the EU  
**PHARMO** – Institute for Drug Outcomes Research (the Netherlands)  
**PHC** – Personalised healthcare  
**PhI** – Pharmacological intelligence  
**PhPID** – Pharmaceutical product identifiers (EU)  
**PhRMA** – Pharmaceutical Research and Manufacturers of America  
**PHS** – Public Health Service (US)  
**PhV** – pharmacovigilance (aka **PV**)  
**PhV WSP WP** – Pharmacovigilance Procedures Work Sharing Working Party  
**PhVIWG** – Pharmacovigilance Inspectors Working Group  
**PhVWP** – Pharmacovigilance Working Party (EMA)  
**PhVWP-V** – Pharmacovigilance Working Party – Veterinary  
**PI** – Package insert – **but also:**  
**PI** – Parallel import – **and also:**  
**PI** – Prescribing information – **and also:**  
**PI** – Principal investigator – **and also:**  
**PI** – Production information – **and also:**  
**PI** – Protease inhibitor  
**PIA** – Pharmaceutical Industries Association  
**PIC** – Pharmaceutical Inspection Convention (EU)  
**PIC/S** – Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme  
**PICO** – Population, intervention, comparator, outcome(s)  
**PICS** – Pharmaceutical inspection cooperation scheme (EU)  
**PIE** – Pharmaceuticals in the environment  
**PIIGS** – Portugal, Ireland, Italy, Greece and Spain  
**PIL** – Patient information leaflet  
**PIM** – Product information management (EMA) – **but also:**  
**PIM** – Promising innovative medicine  
**PIN** – Patient identification number  
**PIP** – Paediatric investigation plan – **but also:**  
**PIP** – Poly Implant Prothèse (breast implant)  
**PIQ** – Product Information Quality Review Group  
**PK** – Pharmacokinetics  
**pKa** – acid dissociation constant  
**PKWP** – Pharmacokinetic Working Party  
**PL** – Package leaflet – **but also:**  
**PL** – Product license (US)  
**PLA** – Product license application (for biologics) (US)  
**PLPI** – Parallel import licence [product licence parallel import]  
**PLR** – Physician Labeling Rule (US)  
**PLR** – Product license renewal (US) – **but also:**  
**PLT** – Platelet count  
**PMA** – Pre-market approval (application for medical devices) (US)  
**PMC** – Postmarketing commitments (US)  
**PMCF** – Post-market clinical follow-up (studies)  
**PMDA** – Japan's regulatory agency – the Pharmaceutical and Medical Devices Agency (within the Ministry of Health, Labor and Welfare – **MHLW**)  
**PMDI** – Pressurised metered dose inhaler  
**PMDL** – Pharmaceutical and Medical Device Law (Japan)  
**PMN** – Pre-market notification  
**PMR** – Postmarketing requirements (US)  
**PMF** – Plant master file (US and Canada)  
**PMI** – Pharmacological, metabolic and immunological  
**PMOA** – Primary mode of action  
**PMPF** – Post Market Performance Follow-up

**PMPRB** – Patented Medicines Prices Review Board (Canada)  
**PMS** – Postmarket(ing) surveillance – **but also:**  
**PMS** – Product data management service/product management services  
**PMS study** – Post-marketing safety study  
**PNC** – Pre-notification consultation (Canada)  
**PNEC** – Predicted no-effect concentration  
**po** – by mouth/orally [*Latin: per os*]  
**POC** – Proof of concept  
**POCA** – Phonetic and Orthographic Computer Analysis  
**POM** – Prescription-only medicine  
**POM to P** – Prescription-only medicine to pharmacy  
**PONV** – Post-operative nausea and vomiting  
**POP db** – Planned and Ongoing Projects database (an EUnetHTA database)  
**popPK** – Population PK  
**PPA** – Parallel production authorisation  
**PPD** – Protected personal data  
**PPI** – Patient and Public Involvement (UK) – **but also:**  
**PPI** – Patient package insert (US)  
**PPP** – Pregnancy Prevention Programme  
**PPP** – Public-private partnership  
**PPRS** – Pharmaceutical Price Regulation Scheme  
**PPSR** – Proposed Paediatric Study Request (US)  
**PQP** – Prequalification of Medicines Programme (WHO)  
**PR** – Pulse rate  
**PRAC** – Pharmacovigilance Risk Assessment Committee (EMA)  
**PRAG** – PSUR Repository Advisory Group  
**PrAR** – Preliminary Assessment Report  
**PRD-PRV** – Pediatric rare disease priority review voucher (US)  
**PREA** – Paediatric Research Equity Act (US)  
**PREG** – Pandemic Response Expert Group  
**PRIME** – Priority medicines scheme  
**P-RMS** – PSUR reference member state (also see **PSUR**)  
**prn** – as needed (*Latin: pro re nata*)  
**PRO** – Patient reported outcome  
**PRO-AE** – Patient-reported outcomes in adverse event reporting  
**PROM** – Patient-relevant outcome measure  
**PROSPER** – Patient-reported outcomes safety event reporting  
**PROTECT** – Pharmacoepidemiological Research on Outcomes of Therapeutics  
**PRR** – Proportional reporting ratio  
**PRRC** – Person responsible for regulatory compliance  
**PRS** – PIM review system (EU) – also see **PIM**  
**PRSPH** – Potential serious risk to public health  
**PSA** – Parallel scientific advice  
**PSBGL(s)** – Product-specific bioequivalence guideline(s)  
**PSD** – Particle size distribution  
**PSM** – Pre-submission meeting  
**PSMF** – Pharmacovigilance system master file  
**PSP** – Paediatric study plan – **and also:**  
**PSP** – Patient Support Programme  
**PSR** – Periodic summary report – **and also:**  
**PSR** – Product safety reference  
**PSRPH** – Potential Serious Risk to Public Health  
**PSS** – Personal social services  
**PSUR** – Periodic safety update report  
**PSUSA** – PSUR single assessment  
**PT** – Preferred term – **and also:**  
**PT time** – Prothrombin time  
**PtC** – Points to consider.  
**PTD** – Protection of technical documentation  
**PTE** – Patent term extension  
**PuAR** – Public assessment report  
**PUL module** – Performance of the Upper Limb module

**PUMA** – Paediatric-use marketing authorisation  
**PV** – Pharmacovigilance  
**PVAR** – Preliminary Variation Assessment Report  
**PXRD** – Powder xray diffraction

### **QQQ**

**(Q)SAR** – Quantitative structure activity relationships  
**QA** – Quality assurance  
**QALY** – Quality-adjusted life year  
**QbD** – Quality by design  
**QC** – Quality control  
**qd** – once a day [*Latin: quaque die*]  
**qds/qid** – four times a day [*Latin: quater die sumendum/quater in die*]  
**QIDP** – Qualified infectious disease product (US)  
**QMS** – Quality management system  
**QOF** – Quality and Outcomes Framework (NICE, UK)  
**QOL** – Quality of life  
**QoS** – Quality overall summary  
**QP** – Qualified person  
**QPPV** – Qualified person for pharmacovigilance  
**QR(C)** – Quick response (code) (EU)  
**QRD** – Quality review of documents [template]  
**QS** – Quality system  
**QSE** – Quality, safety and efficacy  
**QSIT** – Quality System Inspection Technique (US FDA)  
**QTPP** – Quality target product profile  
**QUAMED** – Quality Medicines for All  
**QWP** – Quality Working Party (EMA)

### **RRR**

**R&D** – Research & development  
**R4BP** – Register for Biocidal Products  
**RA** – Rapid alert – **but also:**  
**RA** – Regulatory affairs  
**RA/NUI System** – Rapid Alert/Non-Urgent Information System  
**RADAR** – Risk assessment of drugs analysis and response  
**RAMA** – Remote access for marketing authorisations (MHRA)  
**RAPS** – Regulatory Affairs Professionals Society (US)  
**RAS** – Rapid alert system  
**RAT** – Regenerative advanced therapy  
**RBC** – Red blood cell count  
**RBI** – Risk-based inspection  
**RBM** – Risk-based monitoring  
**RCB** – Registered certification body (Japan)  
**RCFID** – Registration Certificate for Import of Drug  
**RCH** – Remove clinical hold  
**RCP** – Royal College of Physicians (UK)  
**RCT** – Randomised controlled trial  
**RCTP** – Regenerative and cellular therapy product  
**RDE** – Remote data entry  
**RDI** – Research, development and innovation  
**RDP** – Regulatory data protection  
**RDS** – Repeat dose study  
**RDT** – Rising-dose tolerance  
**REA** – Relative effectiveness assessment  
**REACH** – Registration, evaluation, authorisation and restriction of chemicals  
**REC** – Research Ethics Committee  
**RefMP(s)** – Reference Medicinal Product(s), see also RMP(s)  
**REMS** – Risk evaluation and mitigation strategy (US)  
**RfD** – Reference dose (veterinary)  
**RFDD** – Regional Food and Drug Director (US)  
**RFI** – Request for information

**RfMs** – Requests for modifications  
**RH** – Relative humidity  
**RHSC** – Regulatory Harmonisation Steering Committee  
**RI** – Regulatory intelligence  
**RIM** – Regulatory information management  
**RING** – Regulatory Intelligence Network Group (EU)  
**rINN** – Recommended international non-proprietary name  
**RiskMAP** – Risk minimisation action plan  
**RLD** – Reference listed drug (US)  
**RMM** – Risk minimisation materials – **but also:**  
**RMM** – Risk minimisation measure  
**RMP** – Reference medicinal product – **but also:**  
**RMP** – Risk management plan  
**RMR** – Reaction monitoring report – **but also:**  
**RMR** – Risk management report  
**RMS** – Reference member state (Europe) – **but also:**  
**RMS** – Referentials data management service  
**rMS** – Reporting member state (Europe)  
**ROG** – Regulatory Optimisation Group  
**RoHS** – Restriction of hazardous substances (Directive)  
**ROI** – Residues on ignition – **but also:**  
**ROI** – Return on investment  
**RONAFA** – Reduction of need for antimicrobials in food-producing animals  
**RoW** – Rest of (the) World  
**RP** – Responsible person  
**RPA** – Robotic process automation  
**RPI** – Research Product Identifier (formerly called 'Unique Product Identifier, UPI)  
**RPS** – Regulated product submission  
**RPSGB** – Royal Pharmaceutical Society of Great Britain  
**RQA** – Research quality assurance  
**RR** – Relative risk – **but also:**  
**RR** – Respiratory rate – **and also:**  
**RR** – Risk ratio  
**RR1** – Regional regulatory initiatives  
**RRR** – Relative risk reduction  
**RSA** – Risk share agreement  
**RSI** – Reference safety information – **but also:**  
**RSI** – Request for supplementary information (EU)  
**RTF** – Refusal-to-file (US)  
**RTI** – Respiratory tract infection  
**RTQ** – Response to questions  
**RTRT** – Real time release testing  
**RTT** – Right to Try  
**RU-MRP** – Repeat use mutual recognition procedure  
**RUP** – Repeat use procedure  
**RWD** – Real world data  
**RWE** – Real world evidence  
**Rx** – Prescription

**SSS**  
**S+T** – Sampling and testing  
**SA** – Scientific advice  
**SAARC** – South Asia Association for Regional Cooperation  
**SaaS** – Software as a service  
**SABS** – Safety alert broadcast system  
**SAD** – Single ascending dose (study)  
**SADR** – Serious adverse drug reaction  
**SAE** – Serious adverse event  
**SAG** – Scientific Advisory Group  
**SAL** – Sterility assurance level  
**SaMD** – Software as a Medical Device  
**SAMM** – Safety assessment of marketed medicines (US)



**SANDS** – Supplemental abbreviated new drug submission (Canada)  
**SAP** – Scientific advice procedure – **but also:**  
**SAP** – Statistical analysis plan  
**SAR** – Safety assessment report – **but also:**  
**SAR** – Serious adverse reaction  
**SAT** – Special Action Team (EFPIA)  
**SAWP** – Scientific Advice Working Party  
**SBA/SBOA** – Summary basis of approval (US)  
**SBP** – Similar biotherapeutic product (WHO)  
**sc** – subcutaneous (aka **sq**)  
**SCB** – Scientific Coordination Board  
**SCCS** – Self-controlled case series design  
**SCF** – Scientific Committee for Food (UK)  
**SCOTT** – Ethics and Standing Committee on Therapeutic Trials (Australia)  
**SCT** – Stem cell transplant  
**sCTMP** – somatic Cell Therapy Medicinal Product  
**SD** – Standard deviation  
**SLDC** – Software development lifecycle  
**SDR** – Statistic of disproportionate reporting  
**SDRG** – Study data reviewer’s guide  
**SDTM** – Study Data Tabulation Model (US)  
**SE** – Standard error – **but also:**  
**SE** – Substantially equivalent/substantial equivalence  
**SEAR** – Safety, Efficacy and Adverse Reactions (sub-committee of CSM)  
**SEB** – Subsequent entry biologic  
**SEED Consortium** – Shaping European Early Dialogues Consortium  
**SEND** – Standard for exchange of nonclinical data  
**SFDA** – Formerly China’s State Food and Drug Administration (now CFDA) **but also:**  
**SFDA** – Safety Features Delegated Act – **and also:**  
**SFDA** – Saudi Food & Drug Authority  
**SFFC medicines** – Spurious/falsely-labelled/falsified/counterfeit medicines (US)  
**SGML** – Standard general mark-up language  
**SGOT** – Serum glutamic oxalo-acetic acid transaminase (SGOT = AST)  
**SGPT** – Serum glutamic pyruvic transaminase (SGPT = ALT)  
**SHBG** – Sex-hormone-binding globulin  
**SI** – Statutory instrument  
**SKU** – stock-keeping unit  
**SLA** – Service level agreement  
**SLK/NMCA** – Statens legemiddelverk/Norwegian Medicines Control Agency  
**SmAR** – Summary Assessment Report  
**SMC** – Scottish Medicines Consortium  
**SMDA** – Safe Medical Devices Act (US)  
**SME** – Significant medical event – **but also:**  
**SMEs** – Small and medium-sized enterprises  
**SMF** – Site master file  
**SMO** – Site management organisation  
**SmPAR** – Summary Pharmacovigilance Assessment Report (EU)  
**SmPC** – Summary of product characteristics (aka **SPC** in veterinary sector)  
**SMQ** – Standardised MedDRA query  
**SMS** – Substance data management service  
**SNDA** – supplemental new drug application (US)  
**SNDS** – Supplemental new drug submission (Canada)  
**SNIF** – Summary Notification Information Format  
**SO** – Scientific opinion  
**SOC** – Standard of care – **but also:**  
**SOC** – System organ class  
**SOCMA** – Society of Chemical Manufacturers and Affiliates  
**SOCRA** – Society of Clinical Research Associates (US-based)  
**SOP** – standard operating procedure  
**SOUP** – Software of unknown pedigree  
**SPA** – Special protocol assessment  
**SPC** – Summary of product characteristics (typically for veterinary sector) – **but also:**

**SPC** – Supplementary protection certificate (EU)  
**SPECT** – Single photon emission computed tomography  
**SPIN** – Special interest network  
**SPL** – Structured product labelling (US)  
**SPOR data** – Substance, product, organisation and referential data  
**SPS** – Summary of Pharmacovigilance Systems  
**sq** – subcutaneous (aka **sc**)  
**SQP** – Suitably qualified person  
**SR** – Significant risk  
**SRAs** – Stringent regulatory authorities  
**SRM** – Specified risk materials  
**c** – and also:  
**SRN** – Stroke Research Network (part of NIHR, UK)  
**SSC** – Scientific Steering Committee  
**SSCP** – Summary of safety and clinical performance  
**SSFFC** – Substandard, spurious, falsely labelled, falsified and counterfeit (medical products)  
**SSRI** – Selective serotonin reuptake inhibitor  
**SSU** – Study start up  
**STAMP** – Safe and timely access to medicines for patients  
**stat** – immediately [*Latin: statim*]  
**STD** – Severely toxic dose  
**STED** – Summary technical documentation [for Demonstrating Conformity to the Essential Principles of Safety and Performance of Medical Devices Safety and Performance of Medical Devices]  
**StEM** – Stakeholder engagement meeting (MHRA)  
**STF** – Study tagging files  
**STR** – Stirred tank bioreactors  
**STRPC** – Scientific, Technical and Regulatory Policy Committee (EFPIA)  
**SUD** – Single use device – **but also:**  
**SUD** – Sudden unexpected death  
**SUE** – Serious undesirable effect  
**SUKL** – State Institute for Drug Control (Czech Republic and Slovakia)  
**SUPAC** – Scale-up and post-approval changes  
**SUPAC-IR** – Scale up and post approval changes – immediate release  
**SUPAC-MR** – Scale up and post approval changes – modified release  
**SUSAR** – Suspected unexpected serious adverse reaction  
**SWOT (analysis)** – Strengths, weaknesses, opportunities, threats  
**SWP** – Safety Working Party (CHMP)  
**Sx** – Symptoms

**TTT**  
**t<sub>1/2</sub>** – Terminal half-life of elimination

**TA** – Targeted assessment – **but also:**  
**TA** – Therapeutic area  
**TABST** – Target animal batch safety testing  
**TAG** – Technical Advisory Group (UK's NICE) – **but also:**  
**TAG** – Therapeutic Advisory Group  
**TAS (studies)** – Target animal safety (studies)  
**TATFAR** – TransAtlantic Task Force on Antimicrobial Resistance  
**TBC** – The Biomarker Consortium  
**TBG** – Thyroid binding globulin  
**TCA** – Tricyclic antidepressant  
**TCM** – Traditional Chinese medicine  
**TCP** – Target candidate profile  
**TCT** – Toxicity, Clinical Trials and Therapeutic Efficacy Subcommittee of the CSM (UK)  
**TDD** – Transdermal drug delivery  
**TD-PRV** – Tropical disease priority review voucher (US)  
**TDR** – Totally drug-resistant  
**tds/tid** – three times a day [*Latin: ter die sumendum/ter in die*]  
**TE** – Therapeutic equivalence  
**TEP** – Tissue engineered product  
**TESS** – Tamper evident security seal

**TFEU** – Treaty on the Functioning of the European Union  
**TFM** – Tentative final monograph (US)  
**TGA** – Therapeutic Goods Administration (Australia's regulatory agency) – **but also:**  
**TGA** – Thermogravimetric analysis  
**THMP** – Traditional herbal medicinal product  
**THMPD** – Traditional Herbal Medicinal Products Directive  
**THMRS** – Traditional Herbal Medicines Registration Scheme  
**THR** – Traditional herbal registration  
**TIGes** – Telematic Implementation Group–electronic submissions  
**TIND** – Treatment IND (see **IND**)  
**TK** – Thymidine kinase – **but also:**  
**TK** – Toxicokinetics  
**TLC** – Thin layer chromatography  
**TLV** – Threshold limit value  
**TMF** – Trial Master File  
**TOC** – Table of contents  
**TOD** – Table of decisions  
**TOM** – Target operating model  
**TOPRA** – The Organisation for Professionals in Regulatory Affairs  
**TOPS** – The Over-volunteering Prevention System (database)  
**TPP** – Target product profile  
**TRF** – Tamper-resistant formulation  
**TRIPS** – Trade Related Aspects of Intellectual Property Rights  
**TRK** – Tropomyosin receptor kinase  
**TRL** – Total residue level (veterinary)  
**TSA** – Therapeutic Substances Act  
**TSE** – Transmissible spongiform encephalopathy  
**TTC** – Threshold of toxicological concern  
**TUBITAK** – Scientific and Technological Research Council of Turkey

#### **UUU**

**UAT** – User acceptance testing  
**UCN** – Unique carton number  
**UDI** – Unique device identification  
**UI** – Unique Identifier (according to the FMD)  
**ULTRA** – Unlocking Lifesaving Treatments for Rare-Diseases Act (US)  
**UMBRA** – Unified Methodologies for Benefit–Risk Assessment  
**UMP** – Beijing Union Medical and Pharmaceutical General Corp (the innovative arm of the Chinese Academy of Medical Sciences)  
**UOUP** – User Interface of Unknown Provenance  
**UPS-NF** – United States Pharmacopeia and National Formulary  
**USAN** – United States Approved Name  
**USC** – United States Code  
**USDA** – United States Department of Agriculture  
**USKVBL** – Ústav pro Státní Kontrolu Veterinárních Biopreparátů a Léčiv (Institute for State Control of Veterinary Biologicals and Medicines) (Czech Republic) – **but also:**  
**USKVBL** – Ústav štátnej kontroly veterinárnych biopreparátov a liečiv (Department of State Control of Veterinary Biologicals and Medicaments) (Slovenia)  
**USP** – United States Pharmacopoeia  
**USP-DI** – United States Pharmacopeia-Drug Information  
**USPI** – United States Product Insert  
**USP-NF** – United States Pharmacopeia-National Formulary  
**USR** – Urgent safety restriction  
**UTI** – Urinary tract infection  
**UUP** – Urgent union procedure (European Commission)

#### **VVV**

**VAERS** – Vaccine adverse event reporting system (US)  
**VAESCO** – Vaccine adverse event surveillance & communication  
**VAF** – Virus antibody free  
**VAI** – Voluntary action indicated  
**VAMF** – Vaccine antigen master file

**VAR** – Variation assessment report  
**VarWP** – Working Party on Variation Regulation, also: Variation Working Party  
**VBA** – Value-based assessment  
**VBP** – Value-based pricing  
**VCS** – Viral challenge study  
**VDD** – Veterinary Drugs Directorate (Canada)  
**VeDDRA** – Veterinary Dictionary for Drug Related Affairs  
**VF** – Ventricular failure  
**VHP** – Voluntary harmonisation procedure  
**VICH** – International Cooperation on Harmonization of Technical Requirements for Registration of **Veterinary** Products  
**VIIP** – Verified internet pharmaceutical practice site (US)  
**VMD** – Veterinary Medicines Directorate  
**VMP** – Veterinary medicinal product  
**VMRFG** – Veterinary Mutual Recognition Facilitation Group  
**VNees** – Veterinary non-eCTD electronic submission  
**VPC** – Veterinary Products Committee (UK)  
**VPN** – Virtual private network  
**vPvB** – Very persistent and very bioaccumulative (biocidal products)  
**VSI** – Validation Supplementary Information  
**VTE** – Venous thromboembolism  
**VWP** – Vaccines Working Party

#### **WWW**

**WBC** – White blood cell  
**WC** – Written confirmation (issued by competent authority)  
**WCPB** – Women of childbearing potential  
**WDA** – Wholesale dealer's licence  
**WEBAE** – Web adverse event(s)  
**WEB-RADR (project)** – Recognising Adverse Drug Reactions  
**WEU** – Well-established use  
**WG** – Working Group  
**WGEO** – Working Group of Enforcement Officers (HMA)  
**WHO** – World Health Organization  
**WL** – Warning letter – **but also:**  
**WL** – Wholesale dealer's licence  
**WOCBP** – Women of child-bearing potential  
**WoE** – Weight of evidence  
**WP** – Working Party  
**WRAC** – Worldwide Regulatory Affairs Committee  
**WS** – Work sharing  
**WTO** – World Trade Organisation

#### **XXX**

**XEVIMPD** – Extended EudraVigilance Investigational Medicinal Product Dictionary  
**XEVMPD** – Extended EudraVigilance medicinal products dictionary  
**XEVPRM** – Extended EudraVigilance product report message  
**XML** – Extensible Markup Language  
**XRF** – X-ray fluorescence

#### **ZZZ**

**ZAPI** – Zoonosis Anticipation and Preparedness Initiative  
**ZVA** – Zalu Valsts Agentura (State Agency for Medicines) (Latvia)

*[Last updated January 2020]*